Monday, October 27, 2025
- 8:00AM-8:15AM
-
Abstract Number: 0849
Mortality and Major Adverse Cardiac Events (MACE) with GLP-1 Receptor Agonists in Psoriatic Arthritis
Plenary II (0849–0854)- 8:15AM-8:30AM
-
Abstract Number: 0850
Single-cell RNA-seq analysis of synovial CD4+ T cells identifies a novel biomarker and therapeutic target in human rheumatoid arthritis
Plenary II (0849–0854)- 8:30AM-8:45AM
-
Abstract Number: 0851
Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis
Plenary II (0849–0854)- 8:45AM-9:00AM
-
Abstract Number: 0852
LEVI-04 Significantly Reduces Bone Marrow Lesions and Symptoms in Knee Osteoarthritis: Results from a Phase II RCT
Plenary II (0849–0854)- 9:00AM-9:15AM
-
Abstract Number: 0853
Olink Proteomics Identifies Macrophage Pro-inflammatory Proteins in Maternal Sera Predictive of Fetal Atrioventricular Block Independent of Maternal Health Status
Plenary II (0849–0854)- 9:15AM-9:30AM
-
Abstract Number: 0854
The Assessments in Spondyloarthritis International Society (ASAS) and Spondyloarthritis Research and Treatment Network (SPARTAN) Revised Classification Criteria for Axial Spondyloarthritis: Development and Validation in the Classification of Axial SpA Inception Cohort Study
Plenary II (0849–0854)- 10:00AM-10:15AM
-
Abstract Number: 0855
Certolizumab Pegol to Prevent Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome and Lupus Anticoagulant (IMPACT): Results from Ongoing Recruitment of a Prospective, Single-Arm, Open-Label, Phase 2 Trial
Abstracts: Antiphospholipid Syndrome (0855–0860)- 10:00AM-10:15AM
-
Abstract Number: 0861
Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies
Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II: Basic & Translational Research (0861–0866)- 10:00AM-10:15AM
-
Abstract Number: 0885
MAIT cell-mediated immune modulation in lupus: antigen-driven expansion as a protective strategy
Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (0885–0890)- 10:00AM-10:15AM
-
Abstract Number: 0891
MEthotrexate versus TOcilizumab for treatment of Giant cell Arteritis (METOGiA trial): a multicenter, randomized, controlled trial.
Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA From Bench to Bedside (0891–0896)- 10:00AM-10:15AM
-
Abstract Number: 0867
NLRP3 Inflammasome Impairs Fracture Repair in Rheumatoid Arthritis through RhoA/Rac1-IL1β Axis-Mediated Suppression of Osteoblast Differentiation
Abstracts: Rheumatoid Arthritis – Animal Models (0867–0872)- 10:00AM-10:15AM
-
Abstract Number: 0873
Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis
Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Therapies (0873–0878)- 10:00AM-10:15AM
-
Abstract Number: 0879
Trajectories and risk factors of interstitial lung disease in limited cutaneous systemic sclerosis from the EUSTAR cohort